<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504696</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-555</org_study_id>
    <nct_id>NCT03504696</nct_id>
  </id_info>
  <brief_title>Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma</brief_title>
  <official_title>Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced (Unresectable or Metastatic) Melanoma: A Multicentric, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted with the aim of estimating the effectiveness, safety, patterns
      of use of nivolumab, and characteristics of patients with unresectable or metastatic
      melanoma, treated with nivolumab monotherapy in the ATU setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS) at 1 year</measure>
    <time_frame>at 1 year</time_frame>
    <description>Overall survival (OS) for adult patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the ATU (Temporary Authorization for Use) program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of demographic characteristics of patients with advanced melanoma treated with nivolumab monotherapy in the ATU program</measure>
    <time_frame>at baseline</time_frame>
    <description>Distribution of demographic characteristics of patients with advanced melanoma treated with nivolumab monotherapy in the ATU program using descriptive statistics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics in patients with advanced melanoma treated with nivolumab monotherapy</measure>
    <time_frame>at baseline</time_frame>
    <description>Clinical characteristics will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) at 2 years</measure>
    <time_frame>at 2 years</time_frame>
    <description>Overall survival (OS) for adult patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the ATU (Temporary Authorization for Use) program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>(PFS) will be measured by the time since nivolumab initiation to either the first disease progression date or last known tumor assessment date, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>ORR is the proportion of patients with an objective response. Objective response is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as assessed by RECIST 1.1</measure>
    <time_frame>at 1 year</time_frame>
    <description>PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of treatment patterns</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Details on Prior and Evolution of Current Treatment Patterns will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of select Grade 3, 4, or 5 adverse events (AEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Select AEs include pulmonary, endocrine, gastrointestinal, hepatic, renal, cutaneous, and infusion reactions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Patients with Advanced Melanoma</arm_group_label>
    <description>RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Patients with Advanced Melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab
        in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients included in RIC-Mel Database:

               -  Diagnosed with melanoma and cared for in the participating sites

               -  Patients who have been given appropriate information about RIC-Mel Database aims
                  and who have provided their written consent for data collection and processing
                  before any data collection is carried out

          -  Patients included in French nivolumab ATU program

        Exclusion Criteria:

        â€¢ Patients included in RIC-Mel database having initiated nivolumab before 12-Sep-2014 or
        after 31-Aug-2015, or in the context of a clinical trial

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

